Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB)
treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB …

Background Linezolid is recommended for treating drug-resistant TB. Adverse events are a
concern to prescribers but have not been systematically studied at the standard dose, and …

Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …

The prolonged treatment duration for multidrug-resistant tuberculosis (MDR-TB) makes
linezolid dosing difficult because of adverse effects associated with long-term use. We …

Objectives Patients with highly resistant tuberculosis have few treatment options.
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have …

Background Multidrug-resistant tuberculosis (MDR-TB) patients have been suffering long,
ineffective, and toxic treatment until short-course injectable-free regimens emerged …

A new drug Bedaquiline, a diarylquinoline agent has been approved by the Food and Drug
Administration for the treatment of pulmonary multidrug-resistant tuberculosis. It has been …

Background Rifampicin-resistant tuberculosis (RR-TB) is largely underdetected in
Indonesia. Xpert MTB/RIF (Xpert) has recently been introduced, prioritizing patients at risk of …

Background Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-
TB) treatment. However, among children with MDR-TB, there are no linezolid …

Objectives Multidrug-resistant tuberculosis (MDR-TB) is a major challenge to global health
security. Early identification of MDR-TB patients increases the likelihood of treatment …